Australian Firms Face Higher PBS Fees As Govt Seeks To Cover Assessment Costs
Executive Summary
Australian pharmaceutical companies are facing possible increases in the fees they have to pay for applications to have medicines listed on the Pharmaceutical Benefits Scheme, as the government proceeds with plans to ensure fee revenues cover the full cost of assessment work.
You may also be interested in...
Stability At Last For Drug Innovators And Pricing In Australia
The Australian government has promised not to implement any new therapeutic groups under the Pharmaceutical Benefits Scheme for the next five years, nor will it introduce any new pricing reforms without consulting the innovative drug industry first.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.